Updated on 13 January 2015
avaysa is approved in US as anticoagulant agent
Singapore: Japanese firm, Daiichi Sankyo, has recieved USFDA approval for Savaysa (edoxaban) tablets, an oral, once-daily selective factor Xa-inhibitor, to reduce the risk of stroke and systemic embolism (SE) in patients with non-valvular atrial fibrillation (NVAF).
"The approval of Savaysa demonstrates our commitment to providing new treatment options for cardiovascular diseases with significant unmet needs and reinforces our leadership in factor Xa-inhibition research, which began more than 30 years ago," said Mr Joji Nakayama, representative director, president and chief executive officer, Daiichi Sankyo Company.
"We look forward to making Savaysa available to patients in the US with NVAF and venous thromboembolism, two serious conditions that are expected to double in prevalence by mid-century", he added.
"Savaysa is an important new anticoagulant in the US and has been shown to reduce the risk of stroke and SE with significantly less major bleeding for patients with NVAF," said Mr Glenn Gormley, senior executive officer and global head of R&D, Daiichi Sankyo Company.